Detection of COVID-19 Subjects Using DiaNose Exhalation Test
Primary Purpose
COVID-19
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
DiaNose
Sponsored by
About this trial
This is an interventional other trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
Corona Suspected Subjects
- Subject ≥18 years of age
- Verified exposure to COVID-19 virus
- Physical or Radiological evidence of Pneumonia or other Upper Respiratory Tract Infection
- Subject with at least one of the following symptoms: Fever >37.80c P.O with no alternative source for infection / Cough / Nasal discharge or congestion / Shortness of breath (subjective or objective) with no alternative explanation / Sore throat / Loss of taste and smell / Combination of headache, general malaise, fatigue or other nonspecific URTI (upper respiratory tract infection) symptoms / GI symptoms (not as a signal symptom)
- Subject has undergone PCR test or is about to undergo the test immediately
- Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
- Subject is able and willing to adhere to the required testing
Exclusion Criteria:
- Subject with HIV
- Subject addicted to alcohol and/or drugs
- Subject with active gingivitis
- Subject with COPD (Chronic Obstructive Pulmonary Disease)
- During the last hour before examination the subject ate including chewing gum / smoked/ Drank (any drink beside water)/performed excessive physical activity
- Subject is pregnant (confirmed by subject declaration)
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
DiaNose procedure
Arm Description
all subjects will be required to undergo the DiaNose exhalation test.
Outcomes
Primary Outcome Measures
collecting and analyzing of DiaNose sensors signals from potential VOC markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing COVID 19.
Sensing Features (SFs) extracted from each of the sensors are used for statistical analysis by artificially intelligent/pattern recognition algorithm.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04476927
Brief Title
Detection of COVID-19 Subjects Using DiaNose Exhalation Test
Official Title
Collecting and Evaluating Data of Potential Volatile Biomarkers in the Exhaled Air of Subjects With and Without COVID-19 by DiaNose
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 1, 2020 (Anticipated)
Primary Completion Date
May 30, 2021 (Anticipated)
Study Completion Date
June 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nanose Medical Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study aim is to collect and analyze data of potential Volatile Organic Compounds (VOCs) that could be used for discriminating between patients with and without COVID-19 or with high-risk for COVID-19 by DiaNose breath test.
up to 300 subjects will be enrolled to the study ( 200 COVID-19 suspected and 100 healthy volunteers in two clinical sites (1 in Israel and 1 in US).
DiaNose system is an electronic nose device that can "smell" diseases in the exhaled breath of patients in real time. This approach is non-invasive, simple and save.
The DiaNose prototype system consists the following elements:
A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.
• Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop that is used to activate and save the test measurements.
Detailed Description
This study is a prospective, multi-center research clinical study. The aim of this study is to collect and analyze data of potential Volatile Organic Compounds (VOCs) that could be used for discriminating between patients with and without COVID-19 or with high-risk for COVID-19 by DiaNose. The VOC profile of exhaled breath from subjects with COVID-19 infected suspected; and healthy volunteers, will be collected and analyzed to build and validate a predictive algorithmic model for diagnosing COVID 19.
Subjects which are COVID-19 infected suspected (Group 1); and healthy volunteers (Group 2), will be the study population. The study will encompass a total of up to 300 patients.
The COVID-19 infected suspected study group will be divided for the data analyzing and algorithm building into the following sub-groups (up to 200 subjects):
Sub-Group A: Clinical symptomatic patients with positive Covid-19 test (positive PCR);
Sub-Group B: Asymptomatic patients with positive Covid-19 test (positive PCR)
Sub-Group C: Clinical symptomatic patients with negative Covid-19 test (negative PCR) Additional sub-groups may be added according to clinical symptoms. Up to 100 will be enrolled to the Healthy volunteers' study group. Subjects who meet general entry criteria will be asked to sign the study-specific Informed Consent Form the patient will be required not to eat/ smoke/ chewing gum or drink beverage other than water for one hour prior to the DiaNose exhalation test.
The patient will be asked to blow air into a disposable tube for a few seconds. Subject may be re-enrolled in case of need to perform additional PCR test and/or breath test with DiaNose according to standard of care or due to the study needs.
It is anticipated that it will require approximately 12 months to complete active enrollment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Total of 300 subjects - 200 suspected to COVID-19 and 100 healthy volunteers. all subjects will be undergo the DiaNose test.
For data analysis and algorithm building, subjects will be divided into one of the following study groups:
Group 1: Covid-19 infected suspected (up to 300 subjects)
Sub-Group A: Clinical symptomatic patients with positive Covid-19 test (positive PCR);
Sub-Group B: Asymptomatic patients with positive Covid-19 test (positive PCR)
Sub-Group C: Clinical symptomatic patients with negative Covid-19 test (negative PCR) Additional sub-groups may be added according to clinical symptoms.
Group 2: Healthy volunteers (up to 100 subjects)
Masking
None (Open Label)
Allocation
N/A
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
DiaNose procedure
Arm Type
Experimental
Arm Description
all subjects will be required to undergo the DiaNose exhalation test.
Intervention Type
Device
Intervention Name(s)
DiaNose
Intervention Description
DiaNose system is an electronic nose device that can "smell" diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.
The DiaNose prototype system consists the following elements:
A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.
Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).
Laptop - Laptop is used to activate and save the test measurements.
Primary Outcome Measure Information:
Title
collecting and analyzing of DiaNose sensors signals from potential VOC markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing COVID 19.
Description
Sensing Features (SFs) extracted from each of the sensors are used for statistical analysis by artificially intelligent/pattern recognition algorithm.
Time Frame
1 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Corona Suspected Subjects
Subject ≥18 years of age
Verified exposure to COVID-19 virus
Physical or Radiological evidence of Pneumonia or other Upper Respiratory Tract Infection
Subject with at least one of the following symptoms: Fever >37.80c P.O with no alternative source for infection / Cough / Nasal discharge or congestion / Shortness of breath (subjective or objective) with no alternative explanation / Sore throat / Loss of taste and smell / Combination of headache, general malaise, fatigue or other nonspecific URTI (upper respiratory tract infection) symptoms / GI symptoms (not as a signal symptom)
Subject has undergone PCR test or is about to undergo the test immediately
Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
Subject is able and willing to adhere to the required testing
Exclusion Criteria:
Subject with HIV
Subject addicted to alcohol and/or drugs
Subject with active gingivitis
Subject with COPD (Chronic Obstructive Pulmonary Disease)
During the last hour before examination the subject ate including chewing gum / smoked/ Drank (any drink beside water)/performed excessive physical activity
Subject is pregnant (confirmed by subject declaration)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ravit Peled
Phone
+972 526145354
Email
ravitp@nanosemed.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ravit Peled
Organizational Affiliation
Nanose Medical
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Detection of COVID-19 Subjects Using DiaNose Exhalation Test
We'll reach out to this number within 24 hrs